Epidemiological features of acute and chronic hepatitis B in the Kyrgyz Republic over the 20-year period (1997-2017)

Abstract

Aim. To determine epidemiological features of acute and chronic viral hepatitis B in the Kyrgyz Republic over the period 1997-2017. Меthоds. Analysis was performed on data bases of the National accounting forms on treated cases of acute and chronic hepatitis B cumulated by the Medical Information Centre of the Ministry of Health of Kyrgyz Republic for the period of 1997 to 2017 as well as 384 medical records of patients with chronic hepatitis B treated in the Hepatologic Centre “Tsadmir”.

Results. In the Kyrgyz Republic among all acute cases of acute viral hepatitides, hepatitis A comprises 60.5 %, hepatitis B - 16.9 %, the ratio of unverified non-A non-C viral hepatitis - 15.2%. With the introduction of HBV vaccination of children (2000) and improvement of infectious control in healthcare settings, a decline of acute HBV incidence is observed - from 26.7 0/0000 to 5.3 0/0000 due to the decrease of acute hepatitis B among children and adolescents to isolated cases, adults from risk groups. The highest incidence of acute hepatitis B is recorded in Osh and Bishkek, in Jalal-Abad and Chuy Regions. This can be explained by that in the southern and northern capitals of the Kyrgyz Republic and in the near lying areas with high population density, access to laboratory and instrumental methods of diagnosis of viral hepatitides is better, along with the higher awareness of its inhabitants regarding the prevention compared to other regions. At the same time an increase of chronic hepatitis B incidence is observed. Predominant modes of transmission are medical-parenteral exposure and household contact (60.9 %), with frequent formation of family clusters (23.8 %). Imperfections were found in the early detection, reporting and accounting of cases of chronic viral hepatitides as well as in examination of hepatitis B virus carriers.

Conclusion. The performed analysis of the incidence and prevalence of acute and chronic hepatitis B in the Kyrgyz Republic allowed assessing the dynamics of the epidemiologic situation in the country regarding this disease, revealed shortcomings in the detection and examination of viral hepatitis B carriers, contributed to development of a new guide for epidemiological surveillance of viral hepatitides.

Keywords

acute and chronic hepatitis B / epidemiological situation / incidence / Kyrgyz Republic

References

[1] Guidelines for the prevention, care and treatment of persons with chronic hepatitis B virus infection, WHO, Geneva, 2015.

[2] Novak K.E. Clinical-laboratory and immunomorphological characteristics of chronic viral hepatitis B, C, D + C resulting in cirrhosis of the liver. Epidemiologiya i infektsionnye bolezni. 2011; (1): 14–19. (In Russ.)

[3] Новак К.Е. Клинико-лабораторная и иммуноморфологическая характеристика хронических вирусных гепатитов В, С, В + С с исходом в цирроз печени. Эпидемиол. и инфекц. бол. 2011; (1): 14-19.

[4] Enaleeva D.Sh., Fazylov V.Kh., Sozinov A.S. Khronicheskie virusnye gepatity V, S i D. Rukovodstvo dlya vrachey. (Chronic viral hepatitides B, C, and D. Handbook for physicians.) Moscow. 2011; 463 p. (In Russ.)

[5] Еналеева, Д.Ш., Фазылов В.Х., Созинов А.С. Хронические вирусные гепатиты В, С и D. Руководство для врачей. М.: 2011; 463.

[6] Infektsionnye bolezni. Natsional'noe rukovodstvo. (Infectious diseases. National guide.) Ed. by N.D. Yushchuk, Yu.Ya. Vengerov. Moscow: GEOTAR-Media. 2009; 1: 616–650. (In Russ.)

[7] Инфекционные болезни. Национальное руководство. Под ред. Н.Д. Ющука, Ю.Я. Венгерова. М.: ГЭОТАР-Медиа. 2009; 1: 616-650.

[8] Shayzadina F.M., Britskaya P.M., Alysheva N.O. Specific features of the epidemic process of viral hepatitides. Infektologiya. 2015; 7 (2): 85–88. (In Russ.)

[9] Шайзадина Ф.М., Брицкая П.М., Алышева Н.О. Особенности эпидемического процесса вирусных гепатитов. Инфектология. 2015; 7 (2): 85-88.

[10] Fazylov V.Kh., Yakupova F.M. Family clusters of chro­nic viral hepatitis B: epidemiologic features and results of immunizational prevention. Obshchestvennoe zdorov'e i zdravookhranenie. 2008; (3): 31–34. (In Russ.)

[11] Фазылов В.Х., Якупова Ф.М. Семейные очаги хронического вирусного гепатита В: эпидемиологическая характеристика и результаты иммунопрофилактики. Обществ. здоровье и здравоохранение. 2008; (3): 31-34.

[12] Hepatitis B. Monograph. BMJ Best Practice. 2014.

[13] Onishchenko G.G., Shakhgil'dyan I.V., Mikhaylov M.I. Assessment of effectiveness of mass vaccination against hepatitis B. Mir virusnykh gepatitov. 2009; 78 (3): 22–23. (In Russ.)

[14] Онищенко Г.Г., Шахгильдян И.В., Михайлов М.И. Оценка эффективности массовой вакцинации против гепатита В. Мир вирусных гепатитов. 2009; 78 (3): 22-23.

[15] Сhien R.N., Chiu K.W., Chu C.M. Acute hepatitis in HBsAg carriers: comparisons among clinical features due to HDV superinfection and other etiologies. Chineze J. Gastroenterol., 1991; 90 (19): 9016–9020.

[16] Сhien R.N., Chiu K.W., Chu C.M. Acute hepatitis in HBsAg carriers: comparisons among clinical features due to HDV superinfection and other etiologies. Chineze J. Gastroenterol., 1991; 90 (19): 9016-9020.

[17] Chien Y.C. et al. Incomplete hepatitis B immunization, maternal carrier status, and increased risk of ­liver diseases: a 20-year cohort study of 3,8 million vaccines. Нepatol. 2014; (60): 125–132.

[18] Chien Y.C. et al. Incomplete hepatitis B immunization, maternal carrier status, and increased risk of liver diseases: a 20-year cohort study of 3,8 million vaccines. Нepatol. 2014; (60): 125-132.

[19] Van Der Meeren O. et al. Characterization of an age-response relationship to GSKs´recombinant hepatitis B vaccine in healthy adults: an integrated analysis. Hum. ­Vaccin. Immunother. 2015; 11 (7): 1729–1729.

[20] Van Der Meeren O. et al. Characterization of an age-response relationship to GSKs´recombinant hepatitis B vaccine in healthy adults: an integrated analysis. Hum. Vaccin. Immunother. 2015; 11 (7): 1729-1729.

[21] Bruce M.G et al. Antibody levels and protection after hepatitis B vaccine: results of a 30-year follow up study and response to a booster dose. J. Infect. Dis. 2016; 2014: 16–22.

[22] Bruce M.G et al. Antibody levels and protection after hepatitis B vaccine: results of a 30-year follow up study and response to a booster dose. J. Infect. Dis. 2016; 2014: 16-22.

RIGHTS & PERMISSIONS

Tobokalova S.T., Bekenova D.S., Zairova G.M., Nurmatov Z.S., Nazarbaeva Z.N., Aytieva Z.T.